BACKGROUND: Melanoma is an intractable cancer with a poor prognosis and increasing prevalence worldwide. Specific biomarkers for early diagnosis have yet to be found. MATERIALS AND METHODS: Serum samples from melanoma patients and healthy volunteers were utilized for identifying melanoma marker proteins using a serological proteome approach. Specifically, G361 cell protein spots separated by 2-dimensional gel electrophoresis and transferred to a membrane were incubated with patient sera, and positive spots that reacted with more than 5 serum samples were identified using time of flight mass spectrometry. RESULTS: Only patient sera showed many spots reacted in G361 gels. A total of 13 positive spots were detected and 5 proteins were identified: eukaryotic elongation factor2 (EEF2), enolase1 (ENO1), aldolase A (ALDOA), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and heterogeneous nuclear ribonucleoproteins (HNRNP) A2B1. The mRNAs of four proteins (EEF2, ENO1, ALDOA and HNRNPA2B1) were highly expressed in G361 cells compared with melanocytes. EEF2, ENO1 and ALDOA mRNAs were also frequently expressed in other melanoma cell lines. CONCLUSION: The autoantibody-based proteomic approach was effective for investigating melanoma biomarkers. This study might contribute to the development of a diagnostic device for the early detection of cancer.
BACKGROUND:Melanoma is an intractable cancer with a poor prognosis and increasing prevalence worldwide. Specific biomarkers for early diagnosis have yet to be found. MATERIALS AND METHODS: Serum samples from melanomapatients and healthy volunteers were utilized for identifying melanoma marker proteins using a serological proteome approach. Specifically, G361 cell protein spots separated by 2-dimensional gel electrophoresis and transferred to a membrane were incubated with patient sera, and positive spots that reacted with more than 5 serum samples were identified using time of flight mass spectrometry. RESULTS: Only patient sera showed many spots reacted in G361 gels. A total of 13 positive spots were detected and 5 proteins were identified: eukaryotic elongation factor2 (EEF2), enolase1 (ENO1), aldolase A (ALDOA), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and heterogeneous nuclear ribonucleoproteins (HNRNP) A2B1. The mRNAs of four proteins (EEF2, ENO1, ALDOA and HNRNPA2B1) were highly expressed in G361 cells compared with melanocytes. EEF2, ENO1 and ALDOA mRNAs were also frequently expressed in other melanoma cell lines. CONCLUSION: The autoantibody-based proteomic approach was effective for investigating melanoma biomarkers. This study might contribute to the development of a diagnostic device for the early detection of cancer.
Authors: Stephen A Whelan; Jianbo He; Ming Lu; Puneet Souda; Romaine E Saxton; Kym F Faull; Julian P Whitelegge; Helena R Chang Journal: J Proteome Res Date: 2012-09-20 Impact factor: 4.466
Authors: Jennifer E Green; John S Cooperwood; Equar Taka; Karam Fa Soliman; Carl B Goodman; Romonia Renee Reams Journal: Cancer Genomics Proteomics Date: 2014 Jul-Aug Impact factor: 4.069
Authors: Artur Wnorowski; Mariola Sadowska; Rajib K Paul; Nagendra S Singh; Anna Boguszewska-Czubara; Lucita Jimenez; Kotb Abdelmohsen; Lawrence Toll; Krzysztof Jozwiak; Michel Bernier; Irving W Wainer Journal: Cell Signal Date: 2015-02-20 Impact factor: 4.315
Authors: Jon J Ladd; Timothy Chao; Melissa M Johnson; Ji Qiu; Alice Chin; Rebecca Israel; Sharon J Pitteri; Jianning Mao; Mei Wu; Lynn M Amon; Martin McIntosh; Christopher Li; Ross Prentice; Nora Disis; Samir Hanash Journal: Cancer Res Date: 2012-12-26 Impact factor: 12.701
Authors: Steven Rust; Sandrine Guillard; Kris Sachsenmeier; Carl Hay; Max Davidson; Anders Karlsson; Roger Karlsson; Erin Brand; David Lowne; John Elvin; Matt Flynn; Gene Kurosawa; Robert Hollingsworth; Lutz Jermutus; Ralph Minter Journal: Mol Cancer Date: 2013-02-13 Impact factor: 27.401